SCHEMBL6132513

SCHEMBL6132513

CCCC(COC)OCC1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
FEN1 P39748 3/20 0.43
ALOX5AP P20292 2/20 0.43
SCN9A Q15858 1/20 0.42
GLS O94925 2/20 0.41
BACE1 P56817 2/20 0.40
ACKR3 P25106 1/20 0.40
CTSD P07339 1/20 0.40
NR1H2 P55055 1/20 0.40
HPGD P15428 1/20 0.39
CYP2C9 P11712 1/20 0.39
CHEK2 O96017 1/20 0.39
KDM1A O60341 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
BCHE P06276 2/20 0.37
HTR6 P50406 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695894 0.81 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL772145 0.81 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL22290470 0.81 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL3713506 0.81 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL8574578 0.80 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL3713508 0.80 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL5235533 0.78 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL8240271 0.78 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL13634196 0.78 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2AFEN1
SCHEMBL4428890 0.78 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2AFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 MEN1 1517/4885ALDH1A1 4718/4885MAPT 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.